Annals of Thoracic Medicine
: 2020  |  Volume : 15  |  Issue : 2  |  Page : 102-

Hemoptysis in COVID-19: Observation

Sora Yasri1, Viroj Wiwanitkit2,  
1 KMT Primary Care Center, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India; Department of Tropical Medicine, Hainan Medical University, Haikou, China

Correspondence Address:
Sora Yasri
KMT Primary Care Center, Bangkok

How to cite this article:
Yasri S, Wiwanitkit V. Hemoptysis in COVID-19: Observation.Ann Thorac Med 2020;15:102-102

How to cite this URL:
Yasri S, Wiwanitkit V. Hemoptysis in COVID-19: Observation. Ann Thorac Med [serial online] 2020 [cited 2022 Jun 29 ];15:102-102
Available from:

Full Text


COVID-19 is a new emerging infection. This disease was first discovered in a province of China.[1] The disease already spread to several countries, including Thailand, Singapore, and Korea.[2] As a new disease, the clinical presentation of this new infection is an interesting topic. An important clinical presentation in respiratory disease is hemoptysis. In previous new emerging coronavirus infections such as MRES and SARS, hemoptysis has never been mentioned. Here, the authors would like to discuss on observation on hemoptysis in COVI-19.

From data on 35 patients in our setting (February 20, 2020), Thailand, no patient presents hemoptysis. From summarizing of available published data on 140 patients with COVID-19 from China,[3],[4] two patients present hemoptysis, giving rate equal to 1.43% (95% confidence interval = 0.36%–5.66%). Here, it can show that hemoptysis might be a possible clinical presentation of COVID-19 although it is not common. A practitioner should recognize this clinical possibility.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Hsia W. Emerging new coronavirus infection in Wuhan, China: Situation in early 2020. Case Study Case Rep 2020;10:8-9.
2Yasri S, Wiwanitkit V. Editorial: Wuhan coronavirus outbreak and imported case. Adv Trop Med Public Health Int 2020;10:1-2.
3Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74.
4Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507-13.